Strides Pharma Science Ltd

Strides Pharma Science’s latest SEBI filing confirms no new share encumbrances, underscoring its commitment to transparency, market confidence, and regulatory compliance.

Strides Pharma’s May 18 filings reveal key audit shifts, earnings‑call tweaks and board moves that may signal strategic changes in its global pharma play.

Strides Pharma Science Ltd has reported a strong first quarter for FY 2026, with revenue of Rs. 11,197 million and operational PAT of Rs. 1,140 million, driven by its strategic focus on niche pharmaceuticals and global reach.